UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

September 09, 2014

Sara Hurvitz, MD, highlights key points on the PIK3CA mutation, and addresses several other key topics in the field of breast cancer.

November 21, 2013

Head and neck cancer patients who participated in a swallow preservation protocol were less likely to suffer from the detrimental effects associated with dysphagia, a common complication associated with radiation therapy and chemoradiation therapy.

November 15, 2013

Delivering high-quality cancer care continues to be a daunting problem for the US healthcare system because of a combination of factors, including an aging population, a shrinking work force, the rising cost of therapies, and a complex disease state and treatment regimen.

September 06, 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the design of a phase III trial looking at palbociclib for the treatment of patients with estrogen receptor-positive metastatic breast cancer.

August 19, 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

August 08, 2013

The investigational antibody lambrolizumab demonstrated significant antitumor activity and good response rates as well as a tolerable toxicity profile in patients with melanoma.

July 29, 2013

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses the efficacy of ipilimumab for the treatment of melanoma.

March 04, 2013

Richard Finn, MD, from Jonsson Comprehensive Cancer Center, discusses the rationale for targeting cyclin-dependent kinases 4 and 6 with the novel agent PD 0332991 in breast cancer.

October 09, 2012

Antoni Ribas, MD, from the UCLA Jonsson Comprehensive Cancer Center, discusses a phase I/II trial combining vemurafenib and ipilimumab for metastatic melanoma.

August 23, 2012

Dr. Antoni Ribas, from UCLA Jonsson Comprehensive Cancer Center, on the Benefits of MAPK Inhibition With Dabrafenib and Trametinib

January 18, 2012

The molecular basis behind the relatively high incidence of secondary skin cancers after patients received vemurafenib has been discovered.

November 21, 2011

If IKK kinase, a group of inhibitory proteins, activity is not regulated properly, tumors in the body have the ability to migrate and proliferate.

July 25, 2011

In patients with metastatic melanoma, the BRAF inhibitor vemurafenib led to high objective response rates and durable treatment responses.

May 25, 2011

The past decade has brought a significant increase in attention to the role that food and nutrients might play in fighting cancer.

May 18, 2011

A dendritic cell vaccine under development may increase median survival time in patients with glioblastoma

May 11, 2011

Plenty of children are afraid to go to the doctor. Dennis Slamon used to look forward to it.